Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_1
1
33%
Ph phase_2
1
33%
Ph not_applicable
1
33%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Other(3)

Detailed Status

unknown3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 11 (33.3%)
Phase 21 (33.3%)
N/A1 (33.3%)

Trials by Status

unknown3100%

Recent Activity

0 active trials
Showing 3 of 3
unknownphase_2

A Phase 2 Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) Combined With Doxorubicin Hydrochloride in the Treatment of Metastatic/Unresectable Non-specific Soft Tissue Sarcoma

NCT05138146
unknownnot_applicable

Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A in China

NCT03998345
unknownphase_1

Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A

NCT03950297

Clinical Trials (3)

Showing 3 of 3 trials
NCT05138146Phase 2

A Phase 2 Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) Combined With Doxorubicin Hydrochloride in the Treatment of Metastatic/Unresectable Non-specific Soft Tissue Sarcoma

Unknown
NCT03998345Not Applicable

Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A in China

Unknown
NCT03950297Phase 1

Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3